Avalon GloboCare Corp. reported significant financial challenges in its 10-K filing for the fiscal year ending December 31, 2025, with a net loss of approximately $18.3 million, a substantial increase from a net loss of $7.9 million in the previous year. The company's accumulated deficit now stands at about $105.9 million. Revenue generation remains a critical issue, as the company has not yet developed a sustainable customer base, and its Keto Air breathalyzer product has generated minimal revenue to date. The company anticipates it will take approximately one year to begin generating meaningful revenue from its newly acquired AI platform, Avalon Quantum AI.
In terms of operational changes, Avalon has shifted its focus from cellular therapy to artificial intelligence and consumer health technology. The company completed the acquisition of RPM Interactive, Inc. in December 2025, which has allowed it to develop an AI-driven video generation platform. This acquisition is part of a broader strategy to enhance its technology portfolio and generate near-term revenue. The company has also discontinued its THC breathalyzer project due to funding issues, but it continues to market the Keto Air device, which is FDA-registered and has exclusive distribution rights in North America until July 2025.
Avalon’s operational metrics indicate a limited workforce, with only two full-time employees as of March 2026, and it has faced challenges in scaling its operations. The company is currently in the early stages of commercial testing for the Keto Air product, assessing market demand and refining its marketing strategy. The RPM platform is in beta testing, with plans for a broader launch in Q3 2026, which aims to expand its user base beyond podcasters to a wider range of content creators.
The company’s financial outlook is uncertain, as it reported a working capital deficit of approximately $12.7 million and a cash balance of only $109,000 at year-end. Avalon GloboCare has expressed substantial doubt about its ability to continue as a going concern without raising additional capital. The company plans to pursue equity financing to support its operations, but there are no guarantees that it will be able to secure the necessary funds. The filing highlights the risks associated with its business model, including intense competition in both the consumer health and AI technology markets, which could hinder its ability to achieve profitability.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. develops and markets precision diagnostic consumer products, primarily the KetoAir breathalyzer, which measures ketosis levels to support diabetic and ketogenic diet management. The company previously offered laboratory testing services but has since exited that segment. It operates mainly in the U.S. market, leveraging FDA-cleared medical device technology combined with AI-driven nutrition software, targeting health-conscious consumers through direct online sales and digital marketing channels.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.